PNH drug safety study ends early

NCT ID NCT05741346

Terminated Disease control Sponsor: BioCryst Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 27 times

Summary

This study was for people with paroxysmal nocturnal hemoglobinuria (PNH) who had already been helped by the drug BCX9930 in an earlier study. The goal was to keep giving them the drug and watch for side effects over time. The study was stopped early, and only 28 people took part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Investigative Site

Paris, France
Investigative Site

Budapest, Hungary
Investigative Site

Ampang, Malaysia
Investigative Site

Bloemfontein, South Africa
Investigative Site

Cape Town, South Africa
Investigative Site

Pretoria, South Africa
Investigative Site

Daejeon, South Korea
Investigative Site

Barcelona, Spain
Investigative Site

Valencia, Spain
Investigative Site

Leeds, United Kingdom
Investigative Site

London, United Kingdom

Conditions

Explore the condition pages connected to this study.

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA